We have developed a targeted method to quantify all combinations of methylation on an H3 peptide containing lysines 27 and 36 (H3K27-K36). By using stable isotopes that separately label the histone backbone and its methylations, we tracked the rates of methylation and demethylation in myeloma cells expressing high vs. low levels of the methyltransferase MMSET/WHSC1/NSD2. Following quantification of 99 labeled H3K27-K36 methylation states across time, a kinetic model converged to yield 44 effective rate constants qualifying each methylation and demethylation step as a function of the methylation state on the neighboring lysine. We call this approach MS-based measurement and modeling of histone methylation kinetics (M4K). M4K revealed that, when dimethylation states are reached on H3K27 or H3K36, rates of further methylation on the other site are reduced as much as 100-fold. Overall, cells with high MMSET have as much as 33-fold increases in the effective rate constants for formation of H3K36 mono-and dimethylation. At H3K27, cells with high MMSET have elevated formation of K27me1, but even higher increases in the effective rate constants for its reversal by demethylation. These quantitative studies lay bare a bidirectional antagonism between H3K27 and H3K36 that controls the writing and erasing of these methylation marks. Additionally, the integrated kinetic model was used to correctly predict observed abundances of H3K27-K36 methylation states within 5% of that actually established in perturbed cells. Such predictive power for how histone methylations are established should have major value as this family of methyltransferases matures as drug targets.epigenetics | EZH2 | multiple myeloma | mass spectrometry | histone code S everal lysine residues in the tails of histones can be mono-, di-, or trimethylated from yeast to human. These position-and state-specific modifications have been implicated in many chromatin template activities (1). The critical roles of these modifications are further supported by their association with many physiological alterations and diseases (2-4). Genome-wide ChIP studies have provided extensive information regarding the localization of known histone methylation marks (5-7). However, this approach mainly captures snapshots of histone methylation. Therefore, it is unable to answer how methylation patterns are faithfully reestablished and maintained on newly synthesized or old histones to understand mechanisms of epigenetic inheritance (8, 9).There are eight known histone methyltransferases (HMTs) targeting H3K36, including NSD1/2/3, SETD2, ASH1L, SET-MAR, SMYD2, and SETD3 (10). Among them, MMSET (NSD2/ WHSC1) preferentially methylates nucleosomal H3K36 and is capable of catalyzing the addition of as many as two methyl groups at this site (i.e., an H3K36 dimethylase) (11). By contrast, polycomb repressive complex 2 (PRC2) is the only known HMT for H3K27, consisting of four core subunits: EZH2 (catalytic subunit), EED, SUZ12, and RbAp48. Unlike the constitutively active H3K36 HMT, the ca...